Montelukast For Adolescents And Adults From 15 Years Pharmathen

Montelukast, the active ingredient in Montelukast For Adolescents And Adults From 15 Years Pharmathen, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the maintenance treatment of asthma, prevention of exercise‑induced bronchoconstriction, and relief of allergic rhinitis in patients aged 15 years and older.

GNH USA supplies Montelukast For Adolescents And Adults From 15 Years Pharmathen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway diseases. - Asthma: improves long‑term control and reduces the need for rescue inhalers. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity. - Allergic rhinitis: eases nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood swings, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Neutropenia: reduced white blood cell count. - Severe skin reactions: Stevens‑Johnson syndrome.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric symptoms: report any mood changes promptly. - Avoid use in patients with known hypersensitivity to montelukast or its excipients. - Use with caution in hepatic impairment: dose adjustment may be required. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism and may lower montelukast levels. - Phenobarbital: can decrease drug exposure. - Ketoconazole: may raise plasma concentrations, increasing side‑effect risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Beta‑agonists: additive bronchodilator effect, observe for excessive stimulation.